Relationship between Galectin-1 and preoperative concurrent chemoradiotherapy and prognosis in patients with locally advanced esophageal squamous cell carcinoma
Objective To analyze the relationship between galactolectin Galectin-1(Gal-1)and the effect and prognosis of patients with locally advanced esophageal squamous cell carcinoma(ESCC).Methods From January 2017 to December 2022,82 patients with locally advanced ESCC who underwent concurrent chemoradiotherapy(CCRT)combined with esophageal cancer resection were collected.The expression of Gal-1 in ESCC tissues was analyzed by immunohistochemical staining and evaluated by semi-quantitative immune response score.Pathological complete response(pCR),overall survival(OS)and disease-free survival(DFS)were recorded.Results The expression of Gal-1 was correlated with lymph node invasion(P=0.004),but not with age,sex,clinical stage,T stage,N stage or vascular invasion(P＞0.05).A total of 30 patients achieved pCR.Gal-1 expression in pCR patients was significantly lower than that in patients without pCR[4.00(4.00,4.00)vs.8.00(8.00,12.00),Z=-4.830,P＜0.001].Gal-1 expression predicted preoperative CCRT response to pCR in patients with locally advanced ESCC with an area under the subject operating characteristic curve of 0.801(95%CI:0.698-0.904).Compared with patients with locally advanced ESCC whose Gal-1 expression score was≥6,patients with Gal-1 expression score＜6 had a longer median DFS[9.57(2.1-53.5)months vs.22.1(2.8-55.2)months,P=0.034].The median OS longer[16.7(6.4-53.5)months versus 27.9(2.8-55.2)months,P=0.003).Univariate and multifactorial Cox proportional regression models showed that Gal-1 expression was an independent factor affecting OS and DFS in locally advanced ESCC patients(P＜0.05).Conclusion In patients with locally advanced ESCC undergoing preoperative CCRT,high expression of Gal-1 predicts poor outcome and prognosis.
NETL
NSTL
万方数据
